Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02301819
Other study ID # 25-5-14 V2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2014
Est. completion date January 2023

Study information

Verified date April 2023
Source Na Homolce Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Eligible patients with severe cardiogenic shock will be randomized to one of the two arms: immediate ECMO therapy or early conservative therapy. In the invasive group, veno-arterial ECMO will be implanted according to the local practice with flow settings to ensure sufficient tissue perfusion. With the exception of ECMO implantation in the invasive group, all other diagnostic and therapeutic procedures will be done according to the current standard of care at the tertiary cardiovascular center, including other cardiovascular interventions (i.e. percutaneous coronary intervention or cardiac surgery). Implantation of other mechanical support devices including ECMO in the primary conservative group is allowed in the case of shock progression with rise of serum lactate by 3 mmol/L in comparison with the lowest value during the past 24 hours. Follow-up include visits at 30 days, 6 moths and 12 months.


Recruitment information / eligibility

Status Completed
Enrollment 122
Est. completion date January 2023
Est. primary completion date August 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients must fulfil criteria for rapidly deteriorating (A) or severe (B) cardiogenic shock: A. Rapidly deteriorating cardiogenic shock is defined as progressive hemodynamic instability necessitating repeated bolus administration of vasopressors to maintain mean arterial pressure > 50 mmHg + impaired left ventricle systolic function (Left ventricle ejection fraction (LVEF) < 35% or LVEF 35-55% in case of severe mitral regurgitation or aortic stenosis) or B. In severe cardiogenic shock all following criteria should be met: 1. Hemodynamic: Cardiac Index (CI) < 2.2 L/min/m2 + norepinephrine dose > 0.1 µg/kg/min + dobutamin dose > 5 µg/kg/min or Systolic blood pressure < 100 mmHg + norepinephrine dose > 0.2 µg/kg/min + dobutamin dose > 5 µg/kg/min + (LVEF < 35% or LVEF 35-55% + severe mitral regurgitation or aortic stenosis) 2. Metabolic: Lactate - two consecutive values = 3 mmol/L (with at least 30 min between samples), with non-decreasing trend on steady doses of inotropes and/or vasopressors or SvO2 - two consecutive values < 50% (with at least 30 min between measurements), with non-increasing trend on steady doses of inotropes and/or vasopressors 3. Hypovolemia must be excluded: Central venous pressure > 7 mmHg or pulmonary capillary wedge pressure > 12 mmHg Exclusion Criteria: 1. Age < 18 years 2. Life expectancy lower than 1 year 3. High suspicion of pulmonary emboli or cardiac tamponade as a cause of shock 4. Significant bradycardia or tachycardia which might be responsible for hemodynamic instability and not treated by pacing or cardioversion 5. Cardiac arrest survivors remaining comatose 6. Hypertrophic obstructive cardiomyopathy 7. Peripheral artery disease disabling insertion of outflow cannula to femoral artery 8. Moderate to severe aortic regurgitation 9. Aortic dissection 10. Uncontrolled bleeding or TIMI major bleeding within last 6 months 11. Known encephalopathy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Veno-arterial extracorporeal membrane oxygenation (ECMO)
Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.
Other:
Early conservative therapy according to standard practice
Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.

Locations

Country Name City State
Czechia Regional Hospital Liberec Liberec
Czechia University Hospital Pilsen Pilsen
Czechia General University Hospital Prague
Czechia Na Homolce Hospital Prague Select One

Sponsors (3)

Lead Sponsor Collaborator
Na Homolce Hospital General University Hospital, Prague, University Hospital Pilsen

Country where clinical trial is conducted

Czechia, 

References & Publications (2)

Ostadal P, Rokyta R, Karasek J, Kruger A, Vondrakova D, Janotka M, Naar J, Smalcova J, Hubatova M, Hromadka M, Volovar S, Seyfrydova M, Jarkovsky J, Svoboda M, Linhart A, Belohlavek J; ECMO-CS Investigators. Extracorporeal Membrane Oxygenation in the Ther — View Citation

Ostadal P, Rokyta R, Kruger A, Vondrakova D, Janotka M, Smid O, Smalcova J, Hromadka M, Linhart A, Belohlavek J. Extra corporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): rationale and design of the multicenter randomized trial. Eur J Heart Fail. 2017 May;19 Suppl 2:124-127. doi: 10.1002/ejhf.857. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Composite of death from any cause, resuscitated circulatory arrest, and implantation of another mechanical circulatory support device 30 days
Secondary All-cause mortality 30 days
Secondary All-cause mortality 6 months
Secondary All-cause mortality 12 months
Secondary Neurological outcome (according to Cerebral Performance Category scale) 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT03283995 - Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
Active, not recruiting NCT04325035 - The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock Phase 2
Active, not recruiting NCT05100836 - SURPASS Impella 5.5 Study
Not yet recruiting NCT05106491 - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients N/A
Completed NCT01367743 - Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock Phase 4
Recruiting NCT05728359 - Genomic Determinants of Outcome in Cardiogenic Shock
Recruiting NCT05699005 - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Phase 1
Not yet recruiting NCT06338345 - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients N/A
Completed NCT03436641 - Microcirculation in Cardiogenic Shock
Recruiting NCT03313687 - SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
Recruiting NCT05506449 - The RECOVER IV Trial N/A
Completed NCT04144660 - "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Completed NCT04548739 - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Recruiting NCT04141410 - Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
Not yet recruiting NCT05879276 - Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. Phase 3
Enrolling by invitation NCT05570864 - Score TO Predict SHOCK - STOP SHOCK
Completed NCT02591771 - Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock Phase 2
Terminated NCT02279979 - Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial N/A
Completed NCT01374867 - CardShock Study and Registry N/A
Recruiting NCT00093301 - Levosimendan Versus Dobutamine in Shock Patients Phase 2/Phase 3